Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunological changes in glioblastoma multiforme patients treated with bevacizumab
2022-002700-21Phase 4Active
- Sponsor
- National Institute of Oncology
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bevacizumab in glioblastoma (GBM), sponsored by National Institute of Oncology. Primary endpoint: Overall survival. Started Nov 2022; status: active.
02
Drugs
bevacizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2022-002700-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002700-21.